Aclaris Therapeutics Announces Patent License Agreement with Lilly for Alopecia Areata
25 August 2022 - 9:00PM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced a
non-exclusive patent license agreement with Eli Lilly and Company
(Lilly).
Under the license agreement, Aclaris granted Lilly non-exclusive
rights under certain patents and patent applications that Aclaris
exclusively licenses from The Trustees of Columbia University in
the City of New York, for the use of baricitinib, Lilly’s JAK
inhibitor, to treat alopecia areata (AA). The agreement includes an
upfront payment, regulatory and commercial milestones, and
royalties.
“We are pleased to sign this patent license agreement with
Lilly,” said Jim Loerop, Chief Business Officer of Aclaris. “We
believe access to this patent portfolio is necessary for anyone
intending to commercialize any JAK inhibitor to treat AA. We have
spent considerable resources in licensing and prosecuting our JAK
inhibitor patent portfolio and we intend to continue to pursue
opportunities provided to us by these patent rights.”
Financial terms are not disclosed.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,”
and similar expressions, and are based on Aclaris’ current beliefs
and expectations. These forward-looking statements include Aclaris’
expectations regarding its JAK inhibitor patent portfolio. These
statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such
statements. Risks and uncertainties that may cause actual results
to differ materially include uncertainties inherent in the conduct
of clinical trials, Aclaris’ reliance on third parties over which
it may not always have full control, Aclaris’ ability to enter into
strategic partnerships on commercially reasonable terms, the
uncertainty regarding the COVID-19 pandemic and other risks and
uncertainties that are described in the Risk Factors section of
Aclaris’ Annual Report on Form 10-K for the year ended December 31,
2021 and other filings Aclaris makes with the U.S. Securities and
Exchange Commission from time to time. These documents are
available under the “SEC Filings” page of the “Investors” section
of Aclaris’ website at www.aclaristx.com. Any forward-looking
statements speak only as of the date of this press release and are
based on information available to Aclaris as of the date of this
release, and Aclaris assumes no obligation to, and does not intend
to, update any forward-looking statements, whether as a result of
new information, future events or otherwise.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024